Genzyme Corporation CEO Has $22M Conflict of Interest in Sanofi-Aventis (France) Buyout
BNET -- To read the financial press, Sanofi-Aventisā (SNY) attempted acquisition of Genzyme (GENZ) is surrounded in mystery: The two sides are far apart on price and investors expect the haggling will take all summer. Will they agree a price or will Sanofi walk away, not willing to overpay?